Jump to main content
Jump to site search

Issue 12, 2000
Previous Article Next Article

Spectrofluorimetric determination of moxifloxacin in tablets, human urine and serum

Author affiliations

Abstract

A spectrofluorimetric method to determine the antibiotic moxifloxacin is proposed and was applied to pharmaceuticals, human urine and serum. The fluorimetric method allows the determination of 30–300 ng mL−1 moxifloxacin in aqueous solution containing phosphoric acid–phosphate buffer (pH 8.3) with λexc= 287 nm and λem= 465 nm. Detection and quantification limits were 10 and 30 ng mL−1, respectively, with a relative standard deviation (n = 10) of 2%. This method was applied to the determination of moxifloxacin in three Spanish commercial pharmaceutical formulations. Another variant of the method in micellar medium allows the direct measurement of moxifloxacin in human serum and urine by standard additions. The enhanced fluorescence of moxifloxacin in 8 mM sodium dodecyl sulfate (SDS) solution at pH 4.0 (acetic acidacetate buffer) for λexc = 294 nm and λem = 503 nm shows the same linear range as the aqueous method with a 25% lower slope (with detection and quantification limits of 15 and 60 ng mL−1, respectively, and a relative standard deviation of 1.3%), but permits the background fluorescence for urine and serum blanks to be minimized. Hence, sufficient sensitivity is reached to determine therapeutic concentrations of the drug in urine (average recovery 102 ± 2%) and serum (average recovery 105 ± 2%) samples.

Back to tab navigation

Publication details

The article was received on 25 Jul 2000, accepted on 18 Oct 2000 and first published on 22 Nov 2000


Article type: Paper
DOI: 10.1039/B005991I
Citation: Analyst, 2000,125, 2322-2325
  •   Request permissions

    Spectrofluorimetric determination of moxifloxacin in tablets, human urine and serum

    J. A. Ocaña, F. J. Barragán and M. Callejón, Analyst, 2000, 125, 2322
    DOI: 10.1039/B005991I

Search articles by author

Spotlight

Advertisements